Hoth Therapeutics Inc. Announces the Addition of Dr. Adam Friedman, M.D. to the Company's Scientific Advisory Board
February 25, 2019 08:00 ET
|
Hoth Therapeutics, Inc
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from...
Hoth Therapeutics Inc. Announces Closing of Initial Public Offering
February 20, 2019 17:15 ET
|
Hoth Therapeutics, Inc
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from...
Hoth Therapeutics Inc. Announces Closing of Initial Public Offering
February 20, 2019 16:30 ET
|
Hoth Therapeutics, Inc
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients...
Hoth Therapeutics Inc. Announces Pricing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “HOTH”
February 15, 2019 08:00 ET
|
Hoth Therapeutics, Inc
NEW YORK, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients...